VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE III CLINICAL TRIAL OF TDI01 "ROCK2 INHIBITOR" FOR IDIOPATHIC PULMONARY FIBROSIS

VOLUNTARY ANNOUNCEMENT - TQH3906 “TYK2/JAK1 JH2 ALLOSTERIC INHIBITOR” ACHIEVING POSITIVE PROGRESS IN THE PHASE II CLINICAL TRIAL FOR PLAQUE PSORIASIS

VOLUNTARY ANNOUNCEMENT - "CULMERCICLIB CAPSULE" APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQF3250 “ORALLY ADMINISTERED, BIASED GLP-1 RECEPTOR AGONIST” APPROVED BY THE NMPA AND FDA

VOLUNTARY ANNOUNCEMENT - “ROTIGOTINE PATCH” APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF TRD208 “NON-OPIOID MULTI-TARGET MULTI-MODAL ANALGESIC”

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2025

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-350 "CDH17 ADC" APPROVED BY THE NMPA